Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan N Chi

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621CSusan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Journal of Clinical Investigation|June 15, 2022
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline gliomaSabine Mueller, Jared M Taitt, Javier E Villanueva-Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignanciesDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Pediatric Blood & Cancer|October 15, 2013
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancerNathan J Robison, Federico Campigotto, Susan N Chi, et al.
The Journal of Clinical Investigation|August 21, 2020
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline gliomaSabine Mueller, Jared M Taitt, Javier E Villanueva-Meyer, et al.
Neuro-Oncology|April 9, 2022
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade gliomaTom Rosenberg, Kee Kiat Yeo, Audrey Mauguen, et al.
Pediatric Blood & Cancer|November 3, 2020
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade gliomaKaren D Wright, Xiaopan Yao, Wendy B London, et al.
The Lancet. Digital Health|May 27, 2026
Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort studyAnna Zapaishchykova, John Zielke, Divyanshu Tak, et al.
British Journal of Cancer|February 12, 2026
Paediatric Therapeutic Development Workshop on rhabdoid tumoursClaudia Montiel Equihua, Jan J Molenaar, Itziar Areso, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621CSusan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Journal of Clinical Investigation|June 15, 2022
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline gliomaSabine Mueller, Jared M Taitt, Javier E Villanueva-Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignanciesDavid S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Pediatric Blood & Cancer|October 15, 2013
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancerNathan J Robison, Federico Campigotto, Susan N Chi, et al.
The Journal of Clinical Investigation|August 21, 2020
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline gliomaSabine Mueller, Jared M Taitt, Javier E Villanueva-Meyer, et al.
Neuro-Oncology|April 9, 2022
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade gliomaTom Rosenberg, Kee Kiat Yeo, Audrey Mauguen, et al.
Pediatric Blood & Cancer|November 3, 2020
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade gliomaKaren D Wright, Xiaopan Yao, Wendy B London, et al.
The Lancet. Digital Health|May 27, 2026
Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort studyAnna Zapaishchykova, John Zielke, Divyanshu Tak, et al.
British Journal of Cancer|February 12, 2026
Paediatric Therapeutic Development Workshop on rhabdoid tumoursClaudia Montiel Equihua, Jan J Molenaar, Itziar Areso, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Pageof 9